Every 10-Q that Electromed, Inc. (ELMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELMD filings page.
Electromed, Inc. delivered strong results for the quarter ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was led by homecare sales and faster expansion in the hospital market.
Quarterly net income rose to $3.0 million from $1.9 million, while diluted EPS increased to $0.35 from $0.21, reflecting higher volumes and improved net revenues per device. Gross margin remained high at about 79%, helping operating income grow faster than sales.
The company ended the period with $17.0 million in cash and no borrowings on its $10 million revolving credit facility, and has active share repurchases, having bought back 151,911 shares for $3.9 million under a $10 million authorization.
Electromed, Inc. reported strong growth for the quarter ended December 31, 2025. Net revenues rose to $18,897,000 from $16,255,000, driven mainly by higher homecare sales and increased productivity per sales representative. Gross margin remained high at about 78% of net revenues.
Net income increased to $2,761,000, up from $1,968,000, with diluted earnings per share improving to $0.32 from $0.22. For the first six months, revenue reached $35,784,000 and net income $4,897,000, both well above the prior year.
The company ended the period with cash and cash equivalents of $13,791,000 and total shareholders’ equity of $45,439,000. It entered a new $10,000,000 secured revolving credit facility with no borrowings outstanding and continued its stock repurchase program, retiring 146,441 shares at an average price of $25.72 per share.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.